Auxilium announces first patient dosed in Phase 2b FSS study of CCH Auxilium Pharmaceuticals announced that the first patient was dosed in its Phase 2b study of collagenase clostridium histolyticum, or CCH, for the treatment of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome, or FSS. FSS can be a prolonged, painful condition of the shoulder in which increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint is thought to cause a loss of range of motion in the shoulder and pain. The condition is believed to affect approximately two to five percent of the general adult population and the full duration of the disease can last from approximately one year to up to 3.5 years. Some cases never completely resolve. The majority of cases are currently managed conservatively with prolonged physical therapy and occasionally with steroid injections. It is estimated that approximately 300,000 cases of FSS are diagnosed annually and approximately 10 percent are treated with an invasive intervention such as surgery or manipulation under anesthesia on an annual basis.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.